These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 34118118)

  • 1. Letermovir in lung transplant recipients with cytomegalovirus infection: A retrospective observational study.
    Veit T; Munker D; Barton J; Milger K; Kauke T; Meiser B; Michel S; Zoller M; Nitschko H; Keppler OT; Behr J; Kneidinger N
    Am J Transplant; 2021 Oct; 21(10):3449-3455. PubMed ID: 34118118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emergence of letermovir resistance in solid organ transplant recipients with ganciclovir resistant cytomegalovirus infection: A case series and review of the literature.
    Hofmann E; Sidler D; Dahdal S; Bittel P; Suter-Riniker F; Manuel O; Walti LN; Hirzel C
    Transpl Infect Dis; 2021 Jun; 23(3):e13515. PubMed ID: 33210830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient.
    Jung S; Michel M; Stamminger T; Michel D
    BMC Infect Dis; 2019 May; 19(1):388. PubMed ID: 31068147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection.
    Cherrier L; Nasar A; Goodlet KJ; Nailor MD; Tokman S; Chou S
    Am J Transplant; 2018 Dec; 18(12):3060-3064. PubMed ID: 30286286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients.
    Aryal S; Katugaha SB; Cochrane A; Brown AW; Nathan SD; Shlobin OA; Ahmad K; Marinak L; Chun J; Fregoso M; Desai S; King C
    Transpl Infect Dis; 2019 Dec; 21(6):e13166. PubMed ID: 31487755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Letermovir as Salvage Therapy for Cytomegalovirus Infection in Transplant Recipients.
    Phoompoung P; Ferreira VH; Tikkanen J; Husain S; Viswabandya A; Kumar D; Humar A
    Transplantation; 2020 Feb; 104(2):404-409. PubMed ID: 32000236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Letermovir for Difficult to Treat Cytomegalovirus Infection in Lung Transplant Recipients.
    Veit T; Munker D; Kauke T; Zoller M; Michel S; Ceelen F; Schiopu S; Barton J; Arnold P; Milger K; Behr J; Kneidinger N
    Transplantation; 2020 Feb; 104(2):410-414. PubMed ID: 31385924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Letermovir for Secondary Prophylaxis of Cytomegalovirus Infection and Disease after Allogeneic Hematopoietic Cell Transplantation: Results from the French Compassionate Program.
    Robin C; Thiebaut A; Alain S; Sicre de Fontbrune F; Berceanu A; D'Aveni M; Ceballos P; Redjoul R; Nguyen-Quoc S; Bénard N; Pahlavan-Grumel G; Cordonnier C
    Biol Blood Marrow Transplant; 2020 May; 26(5):978-984. PubMed ID: 32035273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytomegalovirus prevention in thoracic organ transplantation: A single-center evaluation of letermovir prophylaxis.
    Saullo JL; Baker AW; Snyder LD; Reynolds JM; Zaffiri L; Eichenberger EM; Ferrari A; Steinbrink JM; Maziarz EK; Bacchus M; Berry H; Kakoullis SA; Wolfe CR
    J Heart Lung Transplant; 2022 Apr; 41(4):508-515. PubMed ID: 35031206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-life use of letermovir prophylaxis for cytomegalovirus in heart transplant recipients.
    Saltiel G; Faure E; Assaf A; Chopin MC; Moreau F; Faure K; Goeminne C; Vuotto F
    Clin Transplant; 2024 May; 38(5):e15327. PubMed ID: 38686437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Letermovir prophylaxis for cytomegalovirus in lung-transplant recipients: a comprehensive study with literature review of off-label use and real-world experiences.
    Hirama T; Shundo Y; Watanabe T; Ohsumi A; Watanabe T; Okada Y
    Clin Exp Med; 2024 Apr; 24(1):68. PubMed ID: 38578337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical "real-world" experience with letermovir for prevention of cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients.
    Anderson A; Raja M; Vazquez N; Morris M; Komanduri K; Camargo J
    Clin Transplant; 2020 Jul; 34(7):e13866. PubMed ID: 32242979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of breakthrough clinically significant cytomegalovirus infection during letermovir prophylaxis in high-risk hematopoietic cell transplant recipients.
    Royston L; Royston E; Masouridi-Levrat S; Chalandon Y; Van Delden C; Neofytos D
    Immun Inflamm Dis; 2021 Sep; 9(3):771-776. PubMed ID: 33949798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients.
    Douglas CM; Barnard R; Holder D; Leavitt R; Levitan D; Maguire M; Nickle D; Teal V; Wan H; van Alewijk DCJG; van Doorn LJ; Chou S; Strizki J
    J Infect Dis; 2020 Mar; 221(7):1117-1126. PubMed ID: 31781762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Letermovir Prophylaxis Decreases Burden of Cytomegalovirus (CMV) in Patients at High Risk for CMV Disease Following Hematopoietic Cell Transplant.
    Johnsrud JJ; Nguyen IT; Domingo W; Narasimhan B; Efron B; Brown JW
    Biol Blood Marrow Transplant; 2020 Oct; 26(10):1963-1970. PubMed ID: 32653623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Refractory and Resistant Cytomegalovirus After Hematopoietic Cell Transplant in the Letermovir Primary Prophylaxis Era.
    Sassine J; Khawaja F; Shigle TL; Handy V; Foolad F; Aitken SL; Jiang Y; Champlin R; Shpall E; Rezvani K; Ariza-Heredia EJ; Chemaly RF
    Clin Infect Dis; 2021 Oct; 73(8):1346-1354. PubMed ID: 33830182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytomegalovirus breakthrough and resistance during letermovir prophylaxis.
    Perchetti GA; Biernacki MA; Xie H; Castor J; Joncas-Schronce L; Ueda Oshima M; Kim Y; Jerome KR; Sandmaier BM; Martin PJ; Boeckh M; Greninger AL; Zamora D
    Bone Marrow Transplant; 2023 Apr; 58(4):430-436. PubMed ID: 36693927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended duration letermovir in allogeneic hematopoietic stem cell transplant.
    Hinman B; Cox J; Umoru G; Kamble R; Musick W
    Transpl Immunol; 2023 Dec; 81():101936. PubMed ID: 37770000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Letermovir for prophylaxis of cytomegalovirus manifestations in adult allogeneic hematopoietic stem cell transplant recipients.
    Hecke SV; Calcoen B; Lagrou K; Maertens J
    Future Microbiol; 2019 Feb; 14():175-184. PubMed ID: 30644320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by
    Chou S; Satterwhite LE; Ercolani RJ
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.